ArticleGland surgery2025
Identification of high- and low-risk groups for ipsilateral recurrence within 10 years after breast-conserving surgery for ductal carcinoma in situ and personalized treatment: a retrospective study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bilateral Breast Fibroadenoma With Bilateral Ductal Carcinoma In Situ: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast-conserving surgery (BCS) is widely used for ductal carcinoma in situ (DCIS), but ipsilateral breast tumor recurrence (IBTR) remains a significant clinical challenge, highlighting the need for reliable predictive models to guide personalized treatment strategies. This study aims to fill the gap by developing a predictive model for IBTR in DCIS patients who have undergone BCS. Methods: A cohort of 40,770 DCIS patients who underwent BCS between 2000 and 2008 was identified from the Surveillance, Epidemiology, and End Results dataset. Chi-squared tests and logistic regression analyses were conducted to identify significant predictive factors for IBTR. These variables were incorporated into nomograms predicting the 5- and 10-year recurrence probabilities. The model was then used to categorize patients into risk groups. Results: The nomograms demonstrated good calibration and discriminative ability for predicting 5- and 10-year IBTR probabilities. Patients were stratified into extremely high- and low-risk groups. Among patients receiving adjuvant radiotherapy, those in the standard-risk group showed significantly lower recurrence rates compared to the extremely high-risk group (P<0.001). For the extremely low-risk group, no significant difference in recurrence risk was observed between patients who received adjuvant radiotherapy and those who did not (P=0.065). Conclusions: Patients with a recurrence rate above 10% were classified as extremely high-risk and may benefit from intensified treatment. Conversely, patients with a recurrence rate below 5% were considered extremely low-risk, suggesting that treatment could be safely de-escalated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.